Shares of Endo International PLC (NASDAQ:ENDP) (TSE:ENL) have earned an average recommendation of “Hold” from the twenty-three ratings firms that are presently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, fourteen have issued a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $10.25.

Several brokerages recently commented on ENDP. Citigroup cut their price target on shares of Thor Industries from $78.00 to $70.00 in a research note on Monday, June 17th. Gabelli reiterated a “hold” rating on shares of Endo International in a research note on Wednesday, March 27th. BidaskClub upgraded shares of Zai Lab from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 28th. Cantor Fitzgerald reiterated an “overweight” rating and set a $130.00 price target (up from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. Finally, Canaccord Genuity reiterated a “hold” rating and set a GBX 365 ($4.77) price target on shares of Crest Nicholson in a research note on Wednesday, May 15th.

NASDAQ:ENDP traded down $0.26 during midday trading on Tuesday, hitting $3.69. 5,008,557 shares of the company were exchanged, compared to its average volume of 3,770,808. The stock has a fifty day moving average of $4.40. Endo International has a fifty-two week low of $3.54 and a fifty-two week high of $18.50. The firm has a market capitalization of $882.10 million, a P/E ratio of 1.28 and a beta of 1.16.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings results on Thursday, May 9th. The company reported $0.53 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.42 by $0.11. Endo International had a negative net margin of 18.35% and a negative return on equity of 199.18%. The firm had revenue of $720.00 million for the quarter, compared to analyst estimates of $692.31 million. During the same period last year, the business earned $0.67 EPS. Endo International’s revenue for the quarter was up 2.9% compared to the same quarter last year. Equities analysts predict that Endo International will post 2.17 EPS for the current year.

In other Endo International news, Director Roger H. Kimmel sold 34,951 shares of Endo International stock in a transaction on Monday, June 17th. The shares were sold at an average price of $3.93, for a total value of $137,357.43. Following the transaction, the director now directly owns 148,309 shares in the company, valued at $582,854.37. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.80% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of ENDP. Signition LP acquired a new position in Endo International in the first quarter valued at $139,000. Neuburgh Advisers LLC increased its stake in Endo International by 13.9% in the fourth quarter. Neuburgh Advisers LLC now owns 24,860 shares of the company’s stock valued at $181,000 after purchasing an additional 3,036 shares during the period. Factorial Partners LLC purchased a new stake in shares of Endo International in the first quarter valued at about $193,000. First Quadrant L P CA boosted its holdings in shares of Endo International by 94.7% in the first quarter. First Quadrant L P CA now owns 24,513 shares of the company’s stock valued at $197,000 after acquiring an additional 11,926 shares in the last quarter. Finally, Flinton Capital Management LLC boosted its holdings in shares of Endo International by 13.9% in the fourth quarter. Flinton Capital Management LLC now owns 38,420 shares of the company’s stock valued at $280,000 after acquiring an additional 4,692 shares in the last quarter. Institutional investors own 93.59% of the company’s stock.

Endo International Company Profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Featured Story: How is net asset value different from market price?

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.